Arimoclomol Phase III trial shows safety, but did not meet its primary or secondary efficacy objectives.
- International Workshop Focuses on Defining Prodromal Phases of ALS, FTD
- New Grants Support Six Projects with ‘Ambitious Goal’ of Preventing ALS
- Dealing ALS a New Hand
- Miller School Studies Pave the Way for the First Pre-Symptomatic ALS Trial for Individuals with SOD1 Genetic Mutation
- UM Researchers’ Validation of ALS Biomarker Could Accelerate Development of New Therapies